Beta-adrenergic receptor blockade as a protection against the death of hypoxia.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000526:Alprenolol / Q000627:therapeutic use; D000818:Animals; D004983:Ethanolamines / Q000627:therapeutic use; D005260:Female; D000860:Hypoxia / Q000188:drug therapy*; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009578:Nitrobenzenes / Q000627:therapeutic use; D010096:Oxprenolol / Q000627:therapeutic use; D010627:Phenethylamines / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010869:Pindolol / Q000627:therapeutic use; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012110:Reserpine / Q000494:pharmacology; D013015:Sotalol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D009578:Nitrobenzenes; D010627:Phenethylamines; D010643:Phenoxybenzamine; D010096:Oxprenolol; D000526:Alprenolol; D012110:Reserpine; D011433:Propranolol; D013015:Sotalol; D010869:Pindolol; D011217:Practolol; D010646:Phentolamine